THE EFFECT AND SAFETY OF BERBERINE ON POLYCYSTIC OVARY SYNDROME : A SYSTEMATIC REVIEW
DOI:
https://doi.org/10.53555/nnmhs.v9i5.1683Keywords:
Berberine, Hypothalamic-Pituitary-Gonadal Axis, Insulin resistance, Polycystic ovary syndrome (PCOS)Abstract
The isoquinoline derivative alkaloid known as berberine (BBB) can be found in the Chinese medicinal herbs Coptidis Rhizoma (Huanglian), Cortex Phellodendri (Huangbai), and Hydrastis Canadensis. These three plants are also the sources of berberine. Since the time when Iranians' ancestors first settled the region, they have made advantage of the unique features that B. vulgaris contains and have done so ever since. For instance, the dried fruits of this plant have been used as an ingredient in food. Additionally, the root, bark, leaf, and fruit of this plant have all been widely exploited as a folk medicine for the treatment of a wide variety of ailments. According to study that was carried out in both vitro and in vivo, it was recently discovered that berberine possesses the potential to reduce glucose levels in people who are afflicted with diabetes and obesity. The precise method by which berberine is able to treat diabetes is not fully understood at this time. In the research that Ko and his colleagues conducted, they found that berberine enhanced the insulin/insulin-like growth factor-1 signaling cascade in Min6 cells, which led to an increase in the amount of insulin that was produced in response to glucose stimulation. Pregnancy rates improved with BBR medication only among infertile women who had taken BBR prior to undergoing IVF, as shown by other studies; this was not the case for all infertile women. Other studies indicated that this was not the case. PCOS women who were treated with BBR saw improvements in their hormonal profile, menstrual cycle, and WHR. Only in infertile women who utilized BBR prior to undergoing IVF did BBB show successful in improving pregnancy rates. The BBR was secure. The findings should be treated with some degree of caution due to the limited amount of study and the size of the sample.
References
1. Bulsara J, Patel P, Soni A, Acharya S. A review: Brief insight into Polycystic Ovarian syndrome. Endocr Metab Sci [Internet]. 2021;3:100085. Available from: https://www.sciencedirect.com/science/article/pii/S266639612100008X
2. Taylor , Fritz, Marc A., Pal, Lubna,, Seli, Emre,, HS. Speroff’s clinical gynecologic endocrinology and infertility. 2020.
3. Rudnicka E, Suchta K, Grymowicz M, Calik-Ksepka A, Smolarczyk K, Duszewska AM, et al. Chronic low grade inflammation in pathogenesis of PCOS. Int J Mol Sci. 2021;22(7):3789.
4. Scoot KG, Avchen RN, Hollomon HA. Epidemiology of child developmental problems: The extent of the problems of poor development in children from deprived backgrounds [Internet]. United Nations University. Available from: http://archive.unu.edu/unupress/food/V201e/ch05.htm
5. Park D-W, Lee S-K, Hong SR, Han A-R, Kwak-Kim J, Yang KM. Expression of Kisspeptin and its receptor GPR54 in the first trimester trophoblast of women with recurrent pregnancy loss. Am J Reprod Immunol. 2012 Feb;67(2):132–9.
6. Abraham Gnanadass S, Divakar Prabhu Y, Valsala Gopalakrishnan A. Association of metabolic and inflammatory markers with polycystic ovarian syndrome (PCOS): an update. Arch Gynecol Obstet. 2021;303:631–43.
7. Hoeger KM, Dokras A, Piltonen T. Update on PCOS: consequences, challenges, and guiding treatment. J Clin Endocrinol Metab. 2021;106(3):e1071–83.
8. Mirzaee F, Razmjouei P, Shahrahmani H, Vafisani F, Najaf Najafi M, Ghazanfarpour M. The effect and safety of Berberine on polycystic ovary syndrome: A systematic review. J Obstet Gynaecol (Lahore). 2021;41(5):684–9.
9. Tillhon M, Ortiz LMG, Lombardi P, Scovassi AI. Berberine: new perspectives for old remedies. Biochem Pharmacol. 2012;84(10):1260–7.
10. Song D, Hao J, Fan D. Biological properties and clinical applications of berberine. Front Med. 2020;14:564–82.
11. Wu X-K, Wang Y-Y, Liu J-P, Liang R-N, Xue H-Y, Ma H-X, et al. Randomized controlled trial of letrozole, berberine, or a combination for infertility in the polycystic ovary syndrome. Fertil Steril. 2016;106(3):757–65.
12. Li L, Li C, Pan P, Chen X, Wu X, Ng EHY, et al. A single arm pilot study of effects of berberine on the menstrual pattern, ovulation rate, hormonal and metabolic profiles in anovulatory Chinese women with polycystic ovary syndrome. PLoS One. 2015;10(12):e0144072.
13. Ibáñez L, de Zegher F. Low-dose flutamide-metformin therapy for hyperinsulinemic hyperandrogenism in non-obese adolescents and women. Hum Reprod Update [Internet]. 2006;12(3):243–52. Available from: https://doi.org/10.1093/humupd/dmi054
14. Dumesic DA, Oberfield SE, Stener-Victorin E, Marshall JC, Laven JS, Legro RS. Scientific Statement on the Diagnostic Criteria, Epidemiology, Pathophysiology, and Molecular Genetics of Polycystic Ovary Syndrome. Endocr Rev [Internet]. 2015;36(5):487–525. Available from: https://doi.org/10.1210/er.2015-1018
15. Hayes MG, Urbanek M, Ehrmann DA, Armstrong LL, Lee JY, Sisk R, et al. Genome-wide association of polycystic ovary syndrome implicates alterations in gonadotropin secretion in European ancestry populations. Nat Commun [Internet]. 2015;6(1):7502. Available from: https://doi.org/10.1038/ncomms8502
16. Rutkowska AZ, Diamanti-Kandarakis E. Polycystic ovary syndrome and environmental toxins. Fertil Steril [Internet]. 2016 Sep 15;106(4):948–58. Available from: https://doi.org/10.1016/j.fertnstert.2016.08.031
17. Cheung AP, Cog F. Polycystic Ovary Syndrome: A Contemporary View. J Obstet Gynaecol Canada [Internet]. 2010;32(5):423–5. Available from: https://www.sciencedirect.com/science/article/pii/S1701216316344930
18. Lu L, Hu J, Wu Q, An Y, Cui W, Wang J, et al. Berberine prevents human nucleus pulposus cells from IL?1??induced extracellular matrix degradation and apoptosis by inhibiting the NF??B pathway. Int J Mol Med. 2019;43(4):1679–86.
19. Di Pierro F, Villanova N, Agostini F, Marzocchi R, Soverini V, Marchesini G. Pilot study on the additive effects of berberine and oral type 2 diabetes agents for patients with suboptimal glycemic control. Diabetes, Metab Syndr Obes targets Ther. 2012;213–7.
20. Zhang Y, Sun J, Zhang Y-J, Chai Q-Y, Zhang K, Ma H-L, et al. The effect of berberine on insulin resistance in women with polycystic ovary syndrome: detailed statistical analysis plan (SAP) for a multicenter randomized controlled trial. Trials. 2016 Oct;17(1):512.
21. Rondanelli M, Perna S, Faliva M, Monteferrario F, Repaci E, Allieri F. Focus on metabolic and nutritional correlates of polycystic ovary syndrome and update on nutritional management of these critical phenomena. Arch Gynecol Obstet [Internet]. 2014;290(6):1079–92. Available from: https://doi.org/10.1007/s00404-014-3433-z
22. Saleem F, Rizvi SW. New Therapeutic Approaches in Obesity and Metabolic Syndrome Associated with Polycystic Ovary Syndrome. Cureus. 2017 Nov;9(11):e1844.
23. Gu Y, Zhang Y, Shi X, Li X, Hong J, Chen J, et al. Effect of traditional Chinese medicine berberine on type 2 diabetes based on comprehensive metabonomics. Talanta. 2010;81(3):766–72.
24. Ko B-S, Choi SB, Park SK, Jang JS, Kim YE, Park S. Insulin sensitizing and insulinotropic action of berberine from Cortidis rhizoma. Biol Pharm Bull. 2005;28(8):1431–7.
25. Pan G-Y, Huang Z-J, Wang G-J, Fawcett JP, Liu X-D, Zhao X-C, et al. The antihyperglycaemic activity of berberine arises from a decrease of glucose absorption. Planta Med. 2003;69(07):632–6.
26. An Y, Sun Z, Zhang Y, Liu B, Guan Y, Lu M. The use of berberine for women with polycystic ovary syndrome undergoing IVF treatment. Clin Endocrinol (Oxf). 2014;80(3):425–31.
27. Szydlarska D, Machaj M, Jakimiuk A. History of discovery of polycystic ovary syndrome. Adv Clin Exp Med. 2017;26(3):555–8.
28. Rondanelli M, Infantino V, Riva A, Petrangolini G, Faliva MA, Peroni G, et al. Polycystic ovary syndrome management: a review of the possible amazing role of berberine. Arch Gynecol Obstet. 2020;301(1):53–60.
29. Guan X, Zheng X, Vong CT, Zhao J, Xiao J, Wang Y, et al. Combined effects of berberine and evodiamine on colorectal cancer cells and cardiomyocytes in vitro. Eur J Pharmacol. 2020;875:173031.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Journal of Advance Research in Medical & Health Science (ISSN: 2208-2425)
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Licensing
Ninety Nine Publication publishes articles under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This licensing allows for any use of the work, provided the original author(s) and source are credited, thereby facilitating the free exchange and use of research for the advancement of knowledge.
Detailed Licensing Terms
Attribution (BY): Users must give appropriate credit, provide a link to the license, and indicate if changes were made. Users may do so in any reasonable manner, but not in any way that suggests the licensor endorses them or their use.
No Additional Restrictions: Users may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
